Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CANDY

Financiado

Cerrado

Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy

Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), and intellectual disability (ID) are clinically heterogeneous, often co-occur, affect ~15% of the EU po... ver más

30/06/2025

RADBOUDUMC

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 19 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-11-22

SC1-BHC-01-2019: Understanding causative mechanisms...

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

19 Participantes

RADBOUDUMC

1.62M€ | Lider

ABENGOA SOLAR NEW TECHNOLOGI...

1.22M€ | Participante

KINGS COLLEGE LONDON

825.00K€ | Participante

425.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

COSYN Comorbidity and Synapse Biology in Clinically Overlapping Ps... 6M€ Cerrado

PCI2019-103712 ALTERACION DE LA COMUNICACION ESPACIO-TEMPORAL ENTRE NEURONA... 190K€ Cerrado

GRASAD Uncovering the genetic roots of ASD and ADHD 161K€ Cerrado

PhenoConnectomics Pheno connectomics of human neurodevelopmental diseases 174K€ Cerrado

SAF2012-33484 ANALISIS CRUZADO DE TRASTORNOS PSIQUIATRICOS: CONTRIBUCION D... 140K€ Cerrado

MiND Mastering skills in the training Network for attention defic... 4M€ Cerrado

Duración del proyecto: 67 meses Fecha Inicio: 2019-11-22
Fecha Fin: 2025-06-30

Líder del proyecto

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), and intellectual disability (ID) are clinically heterogeneous, often co-occur, affect ~15% of the EU population; and are associated with somatic illnesses (e.g. epilepsy, autoimmune and gastrointestinal disease) that lead to a significant increase in morbidity and mortality. For instance in ASD the combination of ID and epilepsy is associated with a reduction in lifespan of ~ 20 years; and an economic cost that is greater than cancer, stroke, or dementia. Yet, the research spend on NDDs is less than 1% of those disorders. Hence, we lack effective new treatments for NDDs and do not understand why they co-occur. There is hope, however. Recent evidence shows that rare genetic variants increasing risk for NDDs are shared, converge on final common pathways (e.g. synaptic plasticity, glutamate and GABA neurotransmission, and excitation/inhibition imbalance), and a key role is likely played by immune dysregulation. CANDY’s innovation is to test, for the first time, if NDDs, and their common mental and somatic multi-morbidity, are caused by a combination(s) of common and rare genetic variants and immune activation acting at different ‘sensitive periods’. Our multi-disciplinary team of world leading academics, patient organizations and SMEs will cost-effectively leverage existing EU-funded studies to 1) identify novel mechanisms underpinning NDDs and their multi-morbidity, 2) develop new strategies for prevention and treatment, 3) deliver novel biomarkers to guide early diagnosis, stratification and/or treatment monitoring, and 4) provide open-access databases, translational test batteries, and tools and targets for valorisation. Together we will transform the landscape for people with NDDs and make possible personalized medicine approaches that target particular mechanisms, in specific subgroups of individuals and at different life stages.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores